Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer

Yonsei Medical Journal

Volumn 51, Issue 5, 2010, Pages 692-699

  Lim, Sung Chul ^a   Cho, Hoon ^a   Lee, Tae Bum ^a   Choi, Cheol Hee ^a   Min, Young Don ^a   Kim, Sung Soo ^a   Kim, Kyung Jong ^a  

^a Chonnam National University   (South Korea)

Author keywords

15 pgdh; Colorectal cancer; Cox 2; Cpla2; Mpges 1

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYCLOOXYGENASE 2; CYTOSOLIC PHOSPHOLIPASE A2; VASCULOTROPIN; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; ISOMERASE; PHOSPHOLIPASE A2 GROUP IV; PROSTAGLANDIN E SYNTHASE;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; TUMOR GROWTH; AGED; COLORECTAL TUMOR; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED;

AGED; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GROUP IV PHOSPHOLIPASES A2; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MIDDLE AGED;

EID: 77957938329     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2010.51.5.692     Document Type: Article

References (47)

1. Boyle P, Zaridze DG, Smans M. Descriptive epidemiology of colorectal cancer. Int J Cancer 1985;36:9-18.
2. Annual Report of the Korea Central Cancer Registry. Ministry of Health and Welfare Republic of Korea; 2002.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
4. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18: 7908-7916.
5. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502.
6. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
7. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999;274:10911-10915.
8. Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002;45:98-103.
9. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-8471.
10. Fux R, Schwab M, Thon KP, Gleiter CH, Fritz P. Cyclooxygenase-2 expression in human colorectal cancer is unrelated to overall patient survival. Clin Cancer Res 2005;11:4754-4760.
11. Lim SC, Lee TB, Choi CH, Ryu SY, Min YD, Kim KJ. Prognostic significance of cyclooxygenase-2 expression and nuclear p53 accumulation in patients with colorectal cancer. J Surg Oncol 2008;97:51-56.
12. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Ann Rev Biochem 1986;55:69-102.
13. Balsinde J, Balboa MA, Insel PA, Dennis EA. Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol 1999;39:175-189.
14. Leslie CC. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 1997;272:16709-16712.
15. Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, et al. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 1997;390: 622-625.
16. Forsberg L, Leeb L, Thorén S, Morgenstern R, Jakobsson P. Human glutathione dependent prostaglandin E synthase: gene structure and regulation. FEBS Lett 2000;471:78-82.
17. Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem 2000;275:32775-32782.
18. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000;275: 32783-32792.
19. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA 2003;100:9044-9049.
20. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 2003;278:19396-19405.
21. Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ, et al. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 2001;7:2669-2674.
22. van Rees BP, Sivula A, Thorén S, Yokozaki H, Jakobsson PJ, Offerhaus GJ, et al. Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer 2003;107:551-556.
23. Ensor CM, Tai HH. 15-Hydroxyprostaglandin dehydrogenase. J Lipid Mediat Cell Signal 1995;12:313-319.
24. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai HH, Musiek ES, et al. 15-Hydroxyprostaglandin dehydrogenase is downregulated in colorectal cancer. J Biol Chem 2005;280:3217-3223.
25. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 2006; 103:12098-12102.
26. Thornton AD, Ravn P, Winslet M, Chester K. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg 2006;93:1456-1463.
27. Panel V, Boëlle PY, Ayala-Sanmartin J, Jouniaux AM, Hamelin R, Masliah J, et al. Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase- 2 expression and contributes to prostaglandin E2 production. Cancer Lett 2006;243:255-263.
28. Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S. Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J Pathol 2006;208:356-363.
29. Yoo NJ, Jeong EG, Lee SH, Lee SH. Expression of 15-hydroxyprostaglandin dehydrogenase, a COX-2 antagonist and tumour suppressor, is not altered in gastric carcinomas. Pathology 2007; 39:174-175.
30. Choi JY, Jang KT, Shim YM, Kim K, Ahn G, Lee KH, et al. Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: comparison with positron emission tomography. Ann Surg Oncol 2006;13:1054-1062.
31. Lim SC, Lee TB, Choi CH, Ryu SY, Kim KJ, Min YD. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in colorectal cancers. Yonsei Med J 2007;48:495-501.
32. Petersen S, Haroske G, Hellmich G, Ludwig K, Petersen C, Eicheler W. COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res 2002; 22:1225-1230.
33. Zhang H, Sun XF. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 2002;97:1037-1041.
34. Takaku K, Sonoshita M, Sasaki N, Uozumi N, Doi Y, Shimizu T, et al. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J Biol Chem 2000;275:34013-34016.
35. Hong KH, Bonventre JC, O'Leary E, Bonventre JV, Lander ES. Deletion of cytosolic phosholipase A(2) suppresses Apc(Min)-induced tumorigenesis. Proc Natl Acad Sci USA 2001;98:3935-3939.
36. Dong M, Guda K, Nambiar PR, Rezaie A, Belinsky GS, LambeauG, et al. Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 2003;24:307-315.
37. Ilsley JN, Nakanishi M, Flynn C, Belinsky GS, De Guise S, Adib JN, et al. Cytoplasmic phospholipase A2 deletion enhances colon tumorigenesis. Cancer Res 2005;65:2636-2343.
38. Soydan AS, Tavares IA, Weech PK, Temblay NM, Bennett A. High molecular weight phospholipase A2 and fatty acids in human colon tumors and associated normal tissue. Eur J Cancer 1996; 32A:1781-1787.
39. Dimberg J, Samuelsson A, Hugander A, Söderkvist P. Gene expression of cyclooxygenase-2, group II and cytosolic phospholipase A2 in human colorectal cancer. Anticancer Res 1998;18: 3283-32887.
40. Wendum D, Svrcek M, Rigau V, Boëlle PY, Sebbagh N, Parc R, et al. COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinoma compared with colorectal adenocarcinomas. Mod Pathol 2003;16: 130-136.
41. Dong M, Johnson M, Rezaie A, Ilsley JN, Nakanishi M, Sanders MM, et al. Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis. Clin Cancer Res 2005;11:2265-2271.
42. Laye JP, Gill JH. Phospholipase A2 expression in tumors: a target for therapeutic intervention? Drug Discov Today 2003;8: 710-716.
43. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenoma and cancer. Clin Cancer Res 2001;7:3971-3976.
44. Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, et al. Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 2008;68:3251-3259.
45. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA 2004;101:17468-17473.
46. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006;66:7818-7823.
47. Gee JR, Montoya RG, Khaled HM, Sabichi AL, Grossman HB. Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol 2003;21:266-270.